Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Completed 3Unknown 1Active not recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Endocrine 5Thoracic 1Other solid neoplasm 1NET 1Head & Neck 1Dermatologic 1

Conditions

Colorectal Neoplasms 234Carcinoma, Non-Small-Cell Lung 132Breast Neoplasms 121Glioblastoma 88Ovarian Neoplasms 86Carcinoma, Hepatocellular 69Rectal Neoplasms 64Brain Neoplasms 58Lung Neoplasms 55Neoplasm Metastasis 54Neoplasms 52Colonic Neoplasms 50Fallopian Tube Neoplasms 43Glioma 40Carcinoma, Renal Cell 35Gliosarcoma 34Melanoma 26Adenocarcinoma of Lung 26Pancreatic Neoplasms 23Liver Neoplasms 23Uterine Cervical Neoplasms 21Stomach Neoplasms 21Recurrence 21Triple Negative Breast Neoplasms 18Kidney Neoplasms 16Endometrial Neoplasms 16Esophageal Neoplasms 15Astrocytoma 14Carcinoma, Ovarian Epithelial 13Adenocarcinoma, Bronchiolo-Alveolar 13

Interventions

Everolimus 9Cisplatin 8Temozolomide 6Nivolumab 5Etoposide 5Carboplatin 5Bevacizumab 5lutetium Lu 177 dotatate 4Capecitabine 4pembrolizumab 3Irinotecan 3sintilimab 2dostarlimab 2cabozantinib 2azaspirane 2avelumab 2atezolizumab 2Paclitaxel 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Ipilimumab 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Fluorodeoxyglucose F18 2Disulfides 2zimberelimab 1surufatinib 1selinexor 1pertuzumab 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Neuroendocrine × Bevacizumab × Clear all
NCT03074513 2026-03-11

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
133 enrolled
DermatologicEndocrineHead & NeckOther solid neoplasmThoracic

Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Adenocarcinoma, Mucinous, Adenoma, Islet Cell, Nasopharyngeal Neoplasms, Carcinoma, Merkel Cell, Carcinoma, Neuroendocrine

NCT04705519 2025-03-14

Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma

Peking University

Phase 2 Completed
79 enrolled
Endocrine

Carcinoma, Neuroendocrine

NCT01121939 2016-02-05

Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers

SCRI Development Innovations, LLC

Phase 2 Completed
43 enrolled 9 charts
Endocrine

Carcinoma, Neuroendocrine

NCT00607113 2013-07-18

Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma

M.D. Anderson Cancer Center

Phase 2 Completed
41 enrolled 6 charts
Endocrine

Carcinoma, Neuroendocrine

NCT01203306 2010-09-16

XELBEVOCT

University of Turin, Italy

Phase 2 Unknown
42 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡